John F. Cannon is chair of Stradling's Securities Litigation and Enforcement practice group and a member of the firm's Board of Directors. He is the former chair of the Litigation department and a former Executive Committee member.
Stradling represents companies who seek a sophisticated law firm with highly experienced counsel to guide critical transactions and disputes. With 130 lawyers working out of offices in Newport Beach, Denver Reno, Sacramento, San Diego, San Francisco Santa Barbara, Santa Monica and Seattle, Stradling has positioned itself as one of the west coast's leading business law firms. To learn more about our attorneys and their specific practice and industry experience, please use the search module to the right. * indicates transactions/cases initiated at prior firms.
Represented Prolacta Bioscience, Inc. with its closing of a $35 million Series E Preferred Stock financing. The investors include two Essex Woodlands Funds, Aisling Capital IV, L.P. and Health Evolution Partners Fund I, L.P., all of which focus on investing in products, technologies and global businesses in the healthcare industry.
Represented ReVision Optics in its Series F Preferred Stock Financing for $32 Million with Johnson & Johnson Development Company acting as lead investor. ReVision Optics plans to use the money raised to fund commercialization.
On December 23, 2016, Stradling client Clearlake Capital Group-backed Syncsort Inc., the global leader in Big Iron to Big Data solutions, purchased Trillium Software from Harte Hanks, a global marketing services firm specializing in multi-channel marketing solutions, headquartered in San Antonio, Texas, for $112 million. The acquisition of Trillium will be the largest in Syncsort's history.
On September 19, 2016, Stradling client Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced an exclusive worldwide license agreement providing Tarveda Therapeutics, Inc. rights for the discovery, development and commercialization by Tarveda of products based on Madrigal’s HSP90 Drug Conjugate program, including the lead clinical candidate, PEN-866.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its strategic alliance with Seelos Therapeutics, licensing them the rights to four therapeutic programs. The programs include Ligand’s aplindore program for the treatment of central nervous system disorders, a CRTH2 antagonist program for the treatment of respiratory disorders, a Captisol-enabled acetaminophen program for pain and fever management, and an H3 receptor antagonist program for the treatment of narcolepsy. Under the agreement, Ligand can receive up to $145 million milestone payments, plus royalties.
Stradling represented Sequent Medical, Inc. in its merger with a U.S. subsidiary of Terumo Corporation, a global medical device company. Under the terms of the deal, Terumo acquired Sequent in an all-cash transaction for $380 million ($280 million up front and up to an additional $100 million if certain milestones are achieved).
Represented LogicMonitor, Inc. in a $130 million investment from Providence Strategic Growth (PSG), the growth equity affiliate of Providence Equity Partners, a global private equity firm with $45 billion in assets under management. The investment will be used to continue LogicMonitor’s global market expansion as the leading modern IT infrastructure performance monitoring solution.
Represented Clearlake Capital Group, L.P. backed Inventus Solutions, Inc. in its $232 million acquisition by RPX Corporation (NASDAQ:RPXC).
Represented a public manufacturing company in connection with an internal investigation related to options backdating.
Served as bond counsel for the $130 million Orange County Water District Revenue Refunding Certificates of Participation, Series 2009A.